GOG-3119/ENGOT-en29/TroFuse-033: A phase 3, randomized study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
作者
Bradley J. Monk,Jérôme Alexandre,Luis Manso Sánchez,Elena Ioana Braicu,Radosław Mądry,Antoinetta J. M. Beijers,Alberto Farolfi,Christof Vulsteke,Kosei Hasegawa,Jian-Liu Wang,Jae-Weon Kim,Sumitra S. Ananda,David S.P. Tan,Ruffo Freitas‐Júnior,Sarah Crafton,Destin R. Black,Brian M. Slomovitz,Robert J. Orlowski,Stephan Kruger,Lili Yao